Share This Article:

Klebsiella pneumoniae Carbapenamase (KPC) Outbreak in a Multispeciality Cancer Hospital—An Emerging Superbug

Full-Text HTML XML Download Download as PDF (Size:515KB) PP. 162-170
DOI: 10.4236/aid.2019.93012    311 Downloads   625 Views


Aim: To identify, analyse and control the outbreak of Carbapenamase producing Klebsiella pneumoniae. Objectives: 1) To detect multidrug resistant K. pneumoniae at the earliest and isolate patients. 2) To find out the predisposing causes for the occurrence of this outbreak. 3) To break the chain of infection transmission. 4) To reduce the risk of Hospital acquired infections. Methods: This retrospective study along with the surveillance was conducted from January 2017 to March 2017 at HCG multispecialty cancer hospital, Bangalore, India. Results: Total 15 patients were diagnosed with KPC infection during the first month of the study period. Those affected were mostly Male patients (73%), admitted in ICU (73%) for further treatment. In our study, the incidence of KPC infection was mostly found with bloodstream infections (60%), mostly seen in those with central lines (80%) followed by patients on ventilatory support (66%). Before the outbreak of KPC infection, all the patients (100%) had already been treated with higher antibiotics including Carbapenems. In our study, only nine out of fifteen patients (60%) could be salvaged with treatment and were discharged. Conclusions: Hospital Infection Control Committee’s regular screening and the training of healthcare professionals are vital for the control of the outbreak.

Cite this paper

Sapkota, S. , Ganesan, S. , Priyadarshini, M. , A., S. and Naik, R. (2019) Klebsiella pneumoniae Carbapenamase (KPC) Outbreak in a Multispeciality Cancer Hospital—An Emerging Superbug. Advances in Infectious Diseases, 9, 162-170. doi: 10.4236/aid.2019.93012.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.